Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) has been recommended as first line treatment in chronic myeloid leukemia (CML) since it is considered to be the only treatment modality with curative potential (1;2). HSCT is most successful if it is done early within the first 2 years after diagnosis (3) . Progress with drug treatment (4) and persisting transplantation mortality (5) have challenged the concept of first line transplantation. In view of the improved survival times after the introduction of interferon α (IFN) (6;7) and imatinib (8;9), the question came up of whether first line transplantation is still justified in all suitable patients with a donor, or whether drug treatment should precede transplantation as long as remission is maintained. No randomized study has yet compared outcome of treatment strategies of HSCT vs. drug treatment.
In a simulation of such a study survival of IFN and hydroxyurea (HU)-treated patients of the German CML-study I (10) had been retrospectively compared with that of a matched cohort of transplanted patients registered with the IBMTR (11). Transplantation did not achieve a survival advantage in this historical analysis before year 6 after diagnosis in all patients and not at all in low risk patients during the observation period of up to eight years from diagnosis. Based on 5-year observation, survival with imatinib seems to be even better than that with IFN-based therapy (12) . This has led to the expert recommendation of a trial with imatinib first before proceeding to HSCT (13) .
In order to verify the data obtained from the retrospective study (11), a prospective randomized study was designed to compare treatment outcome in a cohort of patients predefined by eligibility for transplantation. Since randomization had to consider the availability of a donor, availability of a matched related donor was used as a random criterion (genetic randomization). The main goal of the study was to describe and compare survival times in patients treated with HSCT in early For personal use only. on April 12, 2017 . by guest www.bloodjournal.org From chronic phase vs. best available drug treatment. Prognostic score at diagnosis and transplantation risk were taken into account (14;15) . We here report the outcome 11 years after the start of the study.
Patients and Methods

Study protocol
All patients with Philadelphia chromosome (Ph) and/or BCR-ABL positive CML in chronic phase were examined for primary HSCT (age <55 years, no serious comorbidity, no other contraindications, informed consent). Patients eligible for HSCT were then genetically randomized according to availability of a matched related donor to primary HSCT or best available drug treatment. A matched related donor was defined as HLA identical sibling donor, or if a sibling donor was not available, another fully matched family donor.
Patients
Enrollment, allocation, follow-up and analysis of patients are depicted in the flow diagram in Fig. 1. In total, 682 patients fulfilling the inclusion criteria of, and consenting to the protocol were consecutively entered into the study by the participating centers between January 1995 and December 2001 and analyzed as of May 15, 2006 . Survival documentation was complete except for one patient who was lost to follow up. Nineteen patients were excluded by the central data quality control. Fortytwo patients had Ph-and BCR-ABL negative CML and will be analyzed separately. 621 Ph-and/or BCR-ABL positive patients in chronic phase CML were therefore registered and stratified according to eligibility for primary HSCT. Median time from diagnosis to registration was 19 days. 356 of the 621 patients were eligible for transplantation and 354 were randomized to receive either allogeneic HSCT from a related donor (group 1, n=135) or best available drug treatment (group 2, n=219). In two patients the donor status remained unknown.
354 eligible patients were thus used for analysis and comparison. 265 patients were not eligible for transplantation (group 3), due to age (n=213, median age 63 [47-90] years), comorbidity (n=19), other or unknown reasons (n=21) and no consent (n=12). They are included here to allow comparison with other studies e.g. concerning patients' characteristics or survival.
Patients' initial characteristics of all three groups are depicted in Table 1 . There were no differences between the groups eligible for HSCT with or without donor with most variables available for all randomized patients including prognostic score at diagnosis determined according to Hasford et al. (14) which takes into account age, spleen size, platelet count, and percentages of blasts, basophils, and eosinophils in the peripheral blood. 14 patients were less than 20 years old, 5 in the transplant and 9 in the drug treatment group. There were significant differences between patients eligible for HSCT (groups 1 and 2) and those not (group 3).
Differences mainly concerned age, symptoms due to organomegaly, WBC count and differential, hemoglobin, and prognostic score. Transplantation risk (EBMT-score) was determined according to Gratwohl et al. (15) . 
Allogeneic HSCT/transplantation cohort
Out of the 354 patients eligible for HSCT a total of 247 patients received a HSCT, 210 in chronic phase and 37 patients in accelerated and blastic phases. 11 of the 265 not eligible patients (3 older than 55 years) also received HSCT later on. In total 258 of 621 patients (42%) were transplanted.
HSCT was performed at 29 accredited centers in Germany, Switzerland, Austria and Poland. The source of stem cells was peripheral blood in 56 patients (23%), marrow in all others. The median time from diagnosis to transplant from a related donor was ten months (range 2-106 months). The recommended treatment prior to HSCT was HU. IFN therapy had to be terminated not later than 
Drug treatment
At the time of recruitment to this study, the recommended primary drug treatment consisted of IFN in combination with HU (17) . Therapy was started with HU (40 mg/kg and day). After Patients who did not achieve a cytogenetic remission on IFN (<35% Ph + metaphases) within 12-18 months had the option of a MUD transplant.
Statistics
The study had two main goals. Firstly, patients with consent and eligibility to HSCT were to be compared between transplantation with a transplant from a related donor and best available drug treatment and secondly, subject to having received conservative drug treatment and not achieving cytogenetic response within twelve months, patients were then randomized between HU/IFN and idarubicin/ara-C/plus IFN maintenance. Sample size was determined in alliance with the second
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As in the study by Archimbaud et al. (18) all patients eligible for HSCT and with a suitable related donor were scheduled to receive HSCT. The result of HLA-family typing was considered to be equivalent to genetic randomization between HSCT and best available drug treatment. All patients were analysed following the intention to treat principle. Thus "time-to-transplantation" bias could be avoided, i.e. patients assigned to receive a HSCT appropriately had to carry the risk of death while waiting for the day of transplantation. The statistical comparison between both groups benefited from all advantages of statistical randomization: comparable patient characteristics, best possible reduction of selection bias, and identical observation periods within both treatment arms.
Primary end point was survival time from diagnosis to cutpoint of survival curves. In the drug treatment group, survival times of patients who received a MUD transplant were censored at the day of transplantation, if patients were still in first chronic phase because the outcome could not be related to drug treatment anymore. Patients transplanted in accelerated or blastic phase were not censored, since drug treatment had failed before. Prior to the study, it was assumed that survival probabilities of transplanted patients would be less favorable in the beginning, but would be better than those of drug treated patients after an extended period of time. Hence, survival times to first cutpoint (and overall survival) were compared by Kaplan-Meier estimation and Wilcoxon-Gehan test (19) which is to be applied, if survival curves are non-proportional and cross, i.e. if they are rather logistic than exponential functions related (11). The significance level α was chosen to be 0.05 two-sided. Patients' characteristics at baseline were descriptively compared using chi-square test, Student's t-test, or Wilcoxon's two-sample test, as appropriate.
All analyses were performed with the program package SAS.
Molecular analysis
BCR-ABL transcript levels were determined by nested and quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) following current international expert recommendations (20) . Quantification of transcripts was achieved by measuring the BCR-ABL/ABL ratio according to the international scale (20) . A major molecular response was defined by a BCR-ABL/ABL ratio of ≤ 0.1, a complete molecular response by undetectable BCR-ABL transcripts using normal abl as an internal sensitivity control (20) .
Ethics
The protocol followed the Declaration of Helsinki and was approved by the ethics committee of the Fakultät für Klinische Medizin Mannheim of the University of Heidelberg and by local ethics committees of participating centers. Written informed consent was obtained from all patients prior to entering the study.
Results
Survival
All patients: Median survival of all 621 patients was 7.5 years when patients were censored at the time of transplantation in first chronic phase and 8.1 years without censoring. The median observation time for living patients was 8.9 (4.2 -11.2) years. Survival according to prognostic score at diagnosis is depicted in Fig. 2a Survival of all 247 transplanted patients according to EBMT-score is shown in Fig. 2b . Five year survival probabilities were 76% (n=97) for EBMT-scores 0, 1 and 2, 54% (n=125) for scores 3 and 4, and 26% (n=25) for scores 5, 6 and 7 (15) . Survival of drug treated and transplanted patients is in line with published data (14;15) Randomized patients: Fig. 3 shows the survival of the 354 randomized patients by presence or absence of a matched related donor. Survival was better for drug treated patients (no related donor) both for the time until the curves converge (cutpoint) at year 8 (p=0.041) and for the entire observation period up to year 11 (p=0.049) and most marked at three years after diagnosis. At 8 years after diagnosis survival curves are no longer distinct. Survival differences were most pronounced in patients with low risk features at diagnosis (Fig. 4a) (Fig. 4b ). Intermediate and high risk patients were combined, since their survival curves were similar in this study. The survival probabilities after 2, 5, 8 and 10 years of groups 1-3 and of all patients, overall and according to risk profile at diagnosis are shown in Table 2 .
At the time of evaluation 74 of the 135 patients (55%) with related donor and 128 of the 219 patients (60%) without related donor (including 67 recipients of MUD transplants in chronic phase) were still alive. These patients were analyzed for their state of health (signs and symptoms of CML relapse such as fatigue, spleen related symptoms, weight loss, fever, anemia, thrombocytopenia and leukopenia, or adverse drug effects). No differences were found between the two groups.
Causes of death
The causes of death are listed and assigned to groups 1-3 in Table 3 . Blast crisis, as expected, was with 42.5% the most frequent cause of death particularly in groups 2a (no related donor available, no MUD-transplant) and 3 (not eligible for HSCT). This was followed by transplant related mortality (26.1%) in groups 1 (related donor available) and 2b (no related donor available, MUD transplant in second line) and by other CML related causes (12.6%). It is noteworthy that with the long survival times observed in this study 17 .6% of all causes of death were not directly CMLrelated.
Current drug treatment
At the time of evaluation 20 of 54 living patients (37%) in group 2 (no related donor available, no MUD transplant) still received IFN or HU, but 31 patients (57%) had been changed to imatinib and other BCR-ABL tyrosine kinase inhibitors afterwards (nilotinib, n=1; dasatinib, n=2)(21;22), mostly after IFN-failure. When patients were censored at the start of imatinib treatment, survival curves did not change indicating that these patients represented a group with more advanced disease and limited response to imatinib.
Cytogenetic and molecular responses
Differences between the transplant and drug treatment groups were found regarding cytogenetic and molecular remissions. All patients surviving at least 5 years and evaluable (group 1: n=113; group 2, no MUD: n=92) were analyzed for cytogenetic and molecular responses (Table 4) .
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Discussion
This is the first trial that quantifies survival after drug treatment and transplantation in CML by randomized controlled comparison. 91% of the patients randomized for transplantation were indeed transplanted demonstrating protocol feasibility and compliance. Four patients (3%) died prior to planned HSCT. Main reason for the high compliance rate was the acceptance of the curative potential of transplantation by most patients. It was ascertained that censoring of MUD patients would not introduce a bias against the HSCT group. MUD patients had even slightly better prognostic scores than the rest of the patients without a related donor. In total, transplantation was available to 42% of all patients. Results of transplantation outcome in this study were in line with data of concurrent transplants in the literature (15) .
The superiority of drug treatment in all, and particularly in low-risk patients during the first eight years after diagnosis is evident and significant. Although IFN was used as primary treatment in this study, the results are valid and relevant also in the imatinib era, since survival with primary imatinib treatment is even better. There is no evidence that the situation is different in very young patients (<20 years old). There is no hint so far that the years lost early due to transplant related mortality will be compensated in the course of the transplant group later on. Long-term observations of transplanted CML-patients (5) demonstrate that survival curves continuously decline at a rate of 1% per year due to late transplant related mortality or relapse. It should be replaced by a trial with modern drug treatment first. Exceptions may be patients' preference, very low transplantation risk and economic reasons. HSCT is regarded as an important salvage therapy in patients without optimal response to drug therapy or in early relapse. *95% C.I.: 95% confidence interval. # For one patient, the prognostic score was not available. ‡Additional to groups 1, 2, and 3, two patients eligible for HSCT were added for whom information on donor availability was missing. ## Between diagnosis and two years, reduction in patient number was mainly due to MUD transplants in first chronic phase. * For two patients, availability of a related donor remained unknown. Thus, the patients could not be classified into groups 1, 2a, or 2b.
** Transplanted in accelerated or blastic phase: group 1 (n=4), group 2a (n=15), group 2b (n=0), group 3 (n=1), all patients (n=20).
*** Not directly CML related causes of death were: organ failure (heart, kidney, liver, lung) (n=20), thromboembolism (n=9), other neoplasia (n=9), infection (n=8), suicide (n=4), other (accident, hemorrhage (2), aortic aneurysm, seizures, Creutzfeld-Jakob) (n=6). phase categorized by risk profile at diagnosis (14) . For one patient the prognostic score was not available. The survival times of patients who received an allogeneic transplant in first chronic phase were censored at the day of transplantation. The 620 patients were later stratified according to eligibility to receiving a transplant from a related donor. The survival differences between the three curves were significant (Log-rank test: p = 0.001). m.s.=median survival. The error bars signify 95% confidence intervals (19) . b) Survival of 247 patients who actually received an allogeneic transplant stratified for transplantation risk according to the EBMT-score (15) . The survival differences between the three curves were significant (Log-rank test: p < 0.001). The survival times of patients who received an unrelated transplant in first chronic phase were censored at the day of transplantation. The survival differences were significant for the entire period and for the time until the curves converge (first cutpoint, year 8) (Wilcoxon-Gehan test: p = 0.049 and 0.041, respectively). For patients at risk see Table 2 . m.s.=median survival. The error bars signify 95% confidence intervals (19) . 
